Topiramate plus paroxetine in treatment-resistant obsessive–compulsive disorder
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
We report a case of treatment-resistant obsessive-compulsive disorder (OCD) that was successfully treated with a pharmacological augmentation of topiramate plus paroxetine. The patient, a 45-year-old woman, was on a stable dose of paroxetine (40 mg/day) when she was started on topiramate (up to 150 mg/day). After 9 weeks of this treatment, her clinical condition remarkably improved, as indicated by a significant decrease of the evaluation scales (Yale-Brown Obsessive-Compulsive Scale and Clinical Global Impression Scale). Our case suggests that topiramate might be beneficial in augmentation with selective serotonin reuptake inhibitors in patients with treatment-resistant OCD, although further investigations are warranted to confirm our findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799 · cited 5×
“Specifically, her Y-BOCS score decreased from 26 at baseline to 11 after 2 weeks, and then to 6 after 5 weeks without any further change until the end of treatment.”
InfluentialTreatment non-response in OCD: methodological issues and operational definitions
Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., Pato, M., Stein, D., Zohar, J., & International Treatment Refractory OCD Consortium (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002900 · Cited by 416
Self-citation
Cited by
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citationPittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
“Augmentation with topiramate has been of reported benefit in refractory OCD in case reports (Hollander & Dell'Osso, 2006; Vinkers & van der Wee, 2008).”
BackgroundThe role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder
Wu, K., Hanna, G. L., Rosenberg, D. R., & Arnold, P. D. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.007 · Cited by 264
“These primarily include topiramate for which there has been one small randomized controlled trial (Mowla et al., 2010) and a number of open trials (Hollander and Dell’Osso, 2006; Van Ameringen et al., 2006; Berlin et al. 2010).”
Fontenelle, L. F., Oostermeijer, S., Harrison, B. J., Pantelis, C., & Yücel, M. (2011) · Drugs · doi:10.2165/11591790-000000000-00000 · Cited by 234
A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c856de · Cited by 158
Metadata
- Authors
- Hollander, E., & Dell'Osso, B.
- Venue
- International Clinical Psychopharmacology
- Published
- 2006-05
- Volume
- 21
- Issue
- 3
- Pages
- 189-191
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2084026782
- Cited by
- 60
- References
- 2
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Topiramate plus paroxetine in treatment-resistant obsessive–compulsive disorder. https://app.cochat.ai/papers/10.1097/01.yic.0000199453.54799.cc
- The paper
- Hollander, E., & Dell'Osso, B. (2006). Topiramate plus paroxetine in treatment-resistant obsessive–compulsive disorder. International Clinical Psychopharmacology. https://doi.org/10.1097/01.yic.0000199453.54799.cc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.